Bryan Steadman, PhD

Bryan S. has a diverse and extensive work experience in the biopharmaceutical industry. Bryan is currently serving as the Chief Technical Officer and Head of R&D at VitriVax, where they are responsible for building the R&D, Quality, and Manufacturing capabilities for the adoption of the company's ALTA technology platform for vaccines. This platform has the potential to simplify vaccine storage and administration, addressing challenges faced in developing countries.

Prior to their current role, Bryan founded CMC Logic LLC in 2018 and served as a Biopharmaceutical CMC Advisor. In this position, they used their technical and leadership expertise to assist companies in biopharmaceutical product development. Their services included product development strategy, organizational design, and facilitation of technology road-mapping and portfolio decision conferences.

From 2017 to 2018, Bryan worked as the Chief Technology Officer at Universal Cells, a start-up company focusing on gene editing to create universal donor cells for cell therapy. Universal Cells was later acquired by Astellas.

Before that, Bryan served as a Biochemical Engineering Mentor at Montana State University-Bozeman in 2016 and as the Executive Director of Process Development at Amgen from 2012 to 2016. During their time at Amgen, they played a key role in integrating new process technologies and managing CMC diligence and integration efforts for product and technology acquisitions.

Bryan also held the position of Vice President of CMC Operations and Project Management at LigoCyte Inc from 2006 to 2012, where they led CMC activities including process development and outsourcing of GMP production. Additionally, they worked as a Senior Director at Allergan from 2001 to 2005, a Director at Bristol-Myers Squibb from 2000 to 2001, and an Associate Director at Bristol-Myers Squibb from 1995 to 2000.

Bryan began their career at Merck as a Research Fellow from 1989 to 1995. Throughout their career, Bryan has demonstrated expertise in various aspects of biopharmaceutical development, including process development, portfolio management, and strategic planning.

Bryan S. attended the University of Wyoming from 1974 to 1979, where they obtained a Bachelor of Science degree in Microbiology. Bryan then pursued further education at the University of Wyoming from 1980 to 1986, earning a PhD in Environmental Toxicology.